Genomics Ltd. Extends Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
Vertex Pharmaceuticals and Genomics Ltd. have extended their long-standing drug discovery and validation partnership for an additional four years.
Stocks · News reference
Vertex Pharmaceuticals has announced that members of its management team will participate in three upcoming investor conferences.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Vertex Pharmaceuticals and Genomics Ltd. have extended their long-standing drug discovery and validation partnership for an additional four years.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Charles F. Wagner Jr., an officer at Vertex Pharmaceuticals, sold 15,300 shares of common stock valued at approximately $8.37 million.
The article compares two healthcare ETFs: State Street's XPH (Pharmaceuticals) and iShares' IBB (Biotechnology). XPH charges lower fees (0.35% vs 0.44%), offers higher dividend yield (0.4% vs 0.2%), and focuses on smaller pharmaceutical companies that are acquisition targets. IBB is significantly larger with $11.3B in assets under management and holds 243 established biotech firms. The analyst recommends XPH for long-term investors due to the pharmaceutical industry's active M&A activity and smaller companies' takeover potential.
The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.
Vortex Energy Corp. has mobilized field crews to begin a ground gravity survey at its Robinsons River Salt Project in Newfoundland and Labrador.